Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

被引：0
|
作者：
Liu, Qingran [1 ]
Li, Jinpeng [2 ]
Chen, Hua [2 ]
Song, Jinlong [2 ]
机构：
[1] Shandong First Med Univ, Binzhou Peoples Hosp, Dept Intervent Med, Binzhou, Shandong, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Intervent Therapy 1, Jinan 250117, Shandong, Peoples R China
来源：
HEPATOLOGY | 2025年 / 81卷 / 03期
关键词：
D O I：
10.1097/HEP.0000000000001215
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E101 / E102
页数：2
相关论文
共 50 条
  • [21] Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
    Sang, Y. B.
    Lee, C. R.
    Kim, S-G.
    Lee, B.
    Kim, C.
    Chon, H. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1549 - S1550
  • [22] A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
    Hayashi, Hidemi
    Sawada, Koji
    Hasebe, Takumu
    Nakajima, Shunsuke
    Sawada, Jun
    Takiyama, Yuri
    Takiyama, Yumi
    Okumura, Toshikatsu
    Fujiya, Mikihiro
    INTERNAL MEDICINE, 2022, 61 (23) : 3497 - 3502
  • [23] Impact of varices on bleeding risks and overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Park, Jeayeon
    Lee, Dong Ho
    Hur, Moon Haeng
    Bin Lee, Yun
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Yu, Su Jong
    JOURNAL OF HEPATOLOGY, 2024, 80 : S457 - S457
  • [24] Remaining Issues Related to Serum Cytokines in Patients with Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab Combination Treatment
    Nagai, Hidenari
    Mukozu, Takanori
    Matsui, Teppei
    Mohri, Kunihide
    Nagumo, Hideki
    Yoshimine, Naoyuki
    Kobayashi, Kojiro
    Ogino, Yu
    Daido, Yasuko
    Wakui, Noritaka
    Momiyama, Koichi
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ONCOLOGY, 2024, 102 (10) : 828 - 840
  • [25] Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy
    Uojima, Haruki
    Chuma, Makoto
    Hidaka, Hisashi
    Tsuda, Takashi
    Kobayashi, Satoshi
    Hattori, Nobuhiro
    Ogushi, Katsuaki
    Arase, Yoshitaka
    Take, Akira
    Sakaguchi, Yoshihiko
    Tomoko, Ando
    Nishigori, Shuhei
    Wanatanbe, Tsunamasa
    Numata, Kazushi
    Morimoto, Manabu
    Kagawa, Tatehiro
    Kako, Makoto
    Kusano, Chika
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (08) : 865 - 873
  • [26] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
  • [27] Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma
    Matsui, Teppei
    Nagai, Hidenari
    Mukozu, Takanori
    Wakui, Noritaka
    Matsuda, Takahisa
    Igarashi, Yoshinori
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (06) : 1058 - 1066
  • [28] A MACHINE LEARNING MODEL TO PREDICT THE TREATMENT RESPONSE OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Hur, Moon Haeng
    Kim, Bo Hyun
    Song, Byeong Geun
    Sinn, Dong Hyun
    Shin, Hyunjae
    Cho, Yuri
    Park, Youngsu
    Park, Jeayeon
    Ko, Yunmi
    Lee, Yun Bin
    Cho, Eun Ju
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Jeong-Hoon
    HEPATOLOGY, 2024, 80
  • [29] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
  • [30] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
    Rossari, F.
    Tada, T.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Masi, G.
    Bergamo, F.
    Amadeo, E.
    Vitiello, F.
    Foti, S.
    Persano, M.
    Piscaglia, F.
    Scartozzi, M.
    Cascinu, S.
    Rimini, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
12345